The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3369-3372

  Sweeney, Christopher J ^a   Miller, Kathy D ^a   Sissons, Sean E ^c   Nozaki, Shinichi ^c   Heilman, Douglas K ^b   Shen, Jianzhao ^b   Sledge, George W ^a  

^a INDIANA UNIVERSITY   (United States)

^b IU Department of Biostatistics   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; BASIC FIBROBLAST GROWTH FACTOR; DOCETAXEL; ENDOTHELIAL CELL GROWTH FACTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; DRUG SYNERGISM; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035870297     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clinical applications of research on angiogenesis
2. Promotion of microtubule assembly in vitro by taxol
3. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
4. The microtubule-affecting drug paclitaxel has antiangiogenic activity
5. Paclitaxel (Taxol), an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
6. Relationships between the structure of taxol analogues and their antimitotic activity
7. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
8. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor
9. Contact-dependent inhibition of angiogenesis by cardiac fibroblasts in three-dimensional fibrin gels in vitro: Implications for microvascular network remodeling and coronary collateral formation
10. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
11. Population pharmacokenitics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
12. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay
13. Inhibition of endothelial cell function by docetaxel (Taxotere)
14. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
15. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
16. Vascular endothelial growth factor induces expression of the antiapoptotic protein Bcl-2 and Al in vascular endothelial cells
17. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms
18. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors
19. 2-Methoxystradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression
20. Uterine estrogen receptor binding of catecholestrogens and of estetrol [1, 3, 5(10)-estratriene-3, 15α, 16aα, 17β-tetrol]
21. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth
22. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
23. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
24. Carboplatin differentially induces the VEGF stress response in endothelial cells: Potentiation of anti-tumor effects by combination treatment with antibody to VEGF